Randomized study of tailored neoadjuvant chemotherapy according to the expression of tau, topo II alpha, and ERCC1 versus standard chemotherapy in HER2-negative breast cancer

臺大醫院;臺大醫院-外科部;臺大醫院-病理部;臺大醫院-腫瘤醫學部;Lu, Yen-ShenYen-ShenLuYeh, Dah-CherngDah-CherngYehTseng, Ling-MingLing-MingTsengChen, Shou-TungShou-TungChenLien, Huang-ChunHuang-ChunLienChang, Hong-TaiHong-TaiChangChang, Yuan-ChingYuan-ChingChangHuang, Shu-MinShu-MinHuangLin, Ching-HungChing-HungLinCheng, Ann-LiiAnn-LiiChengHuang, Chiun-ShengChiun-ShengHuang鄭安理2017-04-252018-07-092017-04-252018-07-092015http://ntur.lib.ntu.edu.tw//handle/246246/278649[SDGs]SDG3Randomized study of tailored neoadjuvant chemotherapy according to the expression of tau, topo II alpha, and ERCC1 versus standard chemotherapy in HER2-negative breast cancer